Carbonyl sulfide (COS) releasing scaffolds are gaining popularity as hydrogen sulfide (H 2 S) donors through exploitation of the carbonic anhydrase (CA)-mediated hydrolysis of COS to H 2 S. The majority of compounds in this emerging class of donors undergo triggerable decomposition (often referred to as self-immolation) to release COS, and a handful of different COS-releasing structures have been reported. One benefit of this donation strategy is that numerous caged COS-containing core motifs are possible and are poised for development into self-immolative COS/H 2 S donors. Because the intermediate release of COS en route to H 2 S donation requires CA, it is important that the COS donor motifs do not inhibit CA directly. In this work, we investigate the cytotoxicity and CA inhibition properties of different caged COS donor cores, as well as caged CO 2 and CS 2 motifs and non-self-immolative control compounds. None of the compounds investigated exhibited significant cytotoxicity or enhanced cell proliferation at concentrations up to 100 lM in A549 cells, but we identified four core structures that function as CA inhibitors, thus providing a roadmap for the future development of self-immolative COS/H 2 S donor motifs.
Introduction
Hydrogen sulfide (H 2 S), now well established as an important gaseous signaling molecule, has been implicated in a wide variety of physiological processes since its initial recognition in 1996 [1] [2] [3] . H 2 S is produced endogenously and maintained at low (midnanomolar) concentrations, and the administration of exogenous sulfide has been shown to provide a therapeutic benefit in various applications, including reduction of myocardial infarct size, vasodilation, and decrease in inflammation [4, 5] . For example, GYY4137 and AP39, which undergo slow hydrolysis to release H 2 S, have been shown to exhibit anti-inflammatory activity [6, 7] . Additionally, appending H 2 S donor scaffolds to non-steroidal antiinflammatory drugs (NSAIDs) has been used to generate a number of H 2 S-NSAID hybrids including ATB-346 and NBS-1120, which are based on naproxen and aspirin derivatives, respectively ( Fig. 1 ) [8, 9] . Aligned with these positive impacts, new H 2 S donation strategies are emerging rapidly, and a number of H 2 S-releasing compounds are currently in clinical trials [10, 11] . Recent goals in improving upon H 2 S-based therapeutics have included triggerable donation in response to specific (and variable) stimuli, controllable rates of H 2 S release, and the ability to append the H 2 S-releasing moiety to a variety of scaffolds to potentially access H 2 S-drug hybrids.
Building from these needs, our lab recently introduced a new strategy for H 2 S donation by using the triggered decomposition (often referred to as self-immolation) of carbonyl sulfide (COS)-releasing motifs (Fig. 2a) , which leverages the rapid hydrolysis of COS to H 2 S by carbonic anhydrase (CA), a ubiquitous mammalian zinc metalloenzyme that normally catalyzes the hydrolysis of CO 2 under near diffusion-limited rates to regulate blood pH levels and tissue CO 2 transport [12, 13] . Since our initial report [14] , a number of related COS-donating scaffolds have been generated for H 2 S release [15] [16] [17] [18] [19] [20] [21] . Complementing slow-release COS donors, [16] a common strategy has been to engineer self-immolative COS release, which can be activated by different stimuli, including ROS [21] , esterase [15, 18] , light [17, 20] , and bio-orthogonal triggers [19] (selected triggered examples are shown in Fig. 2b ). Moreover, we recently reported on the kinetics of COS release from several different caged carbonyl sulfide isomers and found that COS/H 2 S release profiles can be tuned by structural and isomeric modifications [22] . This work expanded our growing knowledge of potential COS donor scaffolds and provides a resource for researchers wishing to develop COS donor scaffolds to fit a specific need. In addition to providing functional H 2 S donor platforms, the availability of such COS donors may allow for the investigation of COS chemical biology, which has been largely under-studied [23] .
Critical to using these donor scaffolds for COS investigations or for therapeutic H 2 S delivery is the general biocompatibility of the core motifs, including potential direct interactions with CA. The efficient conversion of COS to H 2 S in all of the above scaffolds requires CA, so it is imperative to not only understand the mechanism of CA activity in COS hydrolysis, but also to determine whether any of the COS-donating motifs are functional CA inhibitors. Significant prior research has focused on identifying CA inhibitors for therapeutic uses, such as treatment of glaucoma, epilepsy, and mountain sickness, and is the topic of numerous recent reviews [13, 24, 25] . Because the structural scope of active CA inhibitors is broad and includes many sulfur-containing molecules, including dithiocarbamates and trithiocarbonates [26, 27] , we wanted to determine whether the sulfur-containing cores of possible COSreleasing scaffolds (Fig. 2c) 
Spectroscopic materials
Tris-HCl buffer was prepared from Tris hydrochloride (Sigma Aldrich, 50 mM) and deionized water obtained from a Synergy UV Millipore Water System and adjusted to pH 8.5 with a SevenMulti pH Probe (Mettler Toledo). UV-visible spectra were acquired on a Cary 60 UV-vis spectrometer equipped with a Quantum Northwest TC-1 temperature controller.
Cell culture materials
A549 cells obtained from ATCC (Manassas, VA) were grown in a 5% CO 2 incubator at 37°C in Dulbecco's Modified Eagle Medium (Gibco (Dublin, Ireland), high glucose, phenol red) with 10% FBS (VWR, Radnor, PA) and 1% penicillin streptomycin (Gibco). Cells were passaged (up to p 25) every 1-3 days upon reaching 85-90% confluency. Absorbance measurements were acquired using a Tecan Safire2 microplate reader.
Synthesis
2.4.1. General synthetic procedure A (Fig. 3a) The alcohol, thiol, or amine starting material (1.0 equiv.) was combined with phenyl isothiocyanate or phenyl isocyanate (1.0 equiv.) in anhydrous THF (15 mL) at 0°C, followed by the addition of base (1.2 equiv.). The resultant mixture was stirred at 0°C for 20 min, after which the ice bath was removed, and the reaction mixture was stirred at r.t. until the completion of the reaction as indicated by TLC. The reaction was quenched by adding brine (30 mL), and the aqueous solution was extracted with ethyl acetate (3 Â 15 mL). The organic layers were combined, dried over MgSO 4 , and evaporated under vacuum. The crude products from each reaction were purified by column chromatography.
Compound 1 was prepared from benzyl alcohol and phenyl isothiocyanate in the presence of NaH (yield: 75%). Compound 2 was prepared from benzyl mercaptan and phenyl isocyanate in the presence of NaH (yield: 38%). Compound 6 was prepared from benzyl alcohol and phenyl isocyanate in the presence of TEA (yield: 20%). Compound 9 was prepared from benzyl mercaptan and phenyl isothiocyanate in the presence of NaH (yield: 75%). Compound 14 was prepared from benzyl amine and phenyl isocyanate in the presence of TEA (yield: 88%). Compound 15 was prepared from benzyl amine and phenyl isothiocyanate in the presence of TEA. (yield: 64%). Characterization data for previously-reported compounds 1, 2, 6, 9, 14, and 15 match the reported data [21, [28] [29] [30] [31] [32] .
2.4.2. General synthetic procedure B (Fig. 3b) The alcohol, thiol, or amine starting material (1.0 equiv.) was combined with the phenyl chloroformate reagent (1.0 equiv.) in anhydrous CH 2 Cl 2 (15 mL) at 0°C, followed by the addition of base (1.0 equiv.). The resultant solution was stirred at 0°C for 20 min, after which the ice bath was removed, and the reaction mixture was stirred at r.t. until the completion of the reaction as indicated by TLC. The reaction was quenched by adding brine (30 mL), and the aqueous solution was extracted with ethyl acetate (3 Â 15 m L). The organic layers were combined, dried over MgSO 4 , and evaporated under vacuum. The crude products from each reaction were purified by column chromatography.
Compound 3 was prepared from benzyl alcohol and phenyl chlorothionoformate in the presence of pyridine (yield: 57%). 
Cytotoxicity assays
Stock solutions of the compounds (20 mM, 10 mM, 5 mM, 2 mM) were prepared in DMSO via serial dilution and used to make 100 mM, 50 mM, 25 mM, and 10 mM solutions of each compound in DMEM (no phenol red, no FBS). 96-Well plates were seeded with $20,000 cells/well overnight prior to cytotoxicity experiments. Cells were washed with PBS (Gibco) and incubated with the desired compound or with vehicle (0.5% DMSO) for one hour prior to being washed with PBS and incubated with CCK-8 solution (10% in DMEM). After 1 h, the absorbance at 450 nm was measured on a plate reader, and the cell survival was calculated as a percent of the control and normalized to the vehicle group. The results are expressed as mean ± SD (n = 6).
Determination of CA inhibition
Stock solutions of each compound (20 mM in DMSO), acetazolamide (20 mM in DMSO), p-nitrophenylacetate (pNPA, 15 mM in ethanol), and CA (7.5 mg/mL in Tris buffer) were prepared and stored at 2-4°C until immediately prior to use. pNPA (20 mL) was injected into the Tris HCl buffer (3 mL) immediately followed by the desired compound of interest (7.5 mL) with stirring at 37.00 ± 0.05°C. Data collection began immediately prior to injection of CA (20 mL) and continued until the production of pNP was complete, as determined by a plateau in absorbance at 405 nm. Absorption data were fit to a first-order exponential equation in Origin 8 to obtain pseudo first-order rate data, which are reported in units of s
À1
. All trials were completed in triplicate and rates are reported as mean ± SD (n = 3).
Results

Synthesis of model compounds
The 15 model compounds used in our investigations were prepared using two general procedures. In synthetic procedure A (Fig. 3a) , one equivalent of an alcohol, thiol, or amine was combined with one equivalent of phenyl isothiocyanate or phenyl isocyanate and base and was stirred until completion of the reaction. Following an extraction and purification by column chromatography, compounds 1, 2, 6, 9, and 14-15 were isolated in 20-88% yield. In synthetic procedure B (Fig. 3b) , one equivalent of the alcohol, thiol, or amine starting material was combined with one equivalent of phenyl chloroformate and base. When the reaction was complete, the product was washed, extracted, and purified by column chromatography. Compounds 3-5, 7-8, and 10-13 were isolated in 32-82% yield.
Our initial report of caged COS release utilized an O-alkyl thiocarbamate scaffold, but S-alkyl thiocarbamates and thiocarbonates have also been reported [15, 17, 22] . Depending on the placement of the COS moiety in the caged core, there are different constitutional isomers that can release COS, which motivated our selection of model compounds 1-5 (Fig. 3c) . Similarly, the availability of caged CO 2 compounds, which generate CO 2 /H 2 O rather than COS/H 2 S, prompted our investigation of control compounds 6-8 (Fig. 3d) . Additionally, the recent interest in CS 2 donor development prompted our inclusion of dithiocarbamates 9-10 ( Fig. 3e) [35] . Finally, we included isomers 11-15 as control compounds, which have similar functional motifs but lack the caged COS core (Fig. 3f) . For each of these model compounds, our goal was to determine whether the core structures exerted cytotoxicity or cell proliferative effects and also to measure the CA inhibition profiles for each compound to better guide future COS donor development.
Cytotoxicity evaluation
Prior to measuring CA inhibition profiles, we first measured the cytotoxicity of each compound in A549 human lung adenocarcinoma cells using the CCK-8 cell proliferation assay. We chose concentrations ranging from 10 to 100 lM for each compound, which corresponds to the general concentration ranges typically used in biological experiments that use H 2 S-donating compounds. Incubation of A549 with 10, 25, 50, or 100 mM of each compound did not result in significant cytotoxicity or proliferation, suggesting that the inherent core structures from each model compound do not significantly impact cell viability (Fig. 4) .
Determination of CA inhibitors
To investigate the potential CA inhibition properties of each of the selected scaffolds, we used CA-mediated p-nitrophenyl acetate (pNPA) hydrolysis as a model system for measuring CA activity/inhibition. The CA-mediated hydrolysis of pNPA is slower than the near diffusion-limited hydrolysis of CO 2 , and the p-nitrophenol (pNP) product has a characteristic absorbance at 405 nM from the phenolate form, thus providing a simple method to measure CA activities by UV-vis spectroscopy (Fig. 5a) [36] . For each compound, we measured the rate of pNPA hydrolysis to pNP and compared these observed rates to those of CA alone, as well as the rate in the presence of the common CA inhibitor acetazolamide (AAA, Fig. 5b) . In each case, the rate of production of pNP was then fit directly to a first-order exponential equation. Of the 15 compounds tested, 11 failed to produce significant changes in the rate of pNPA hydrolysis, suggesting that these compounds do not exhibit significant CA inhibition at concentrations typically used in H 2 S donor experiments. Four compounds, however, were found to inhibit CA activity: 2, 9, 12, and 13. Of these compounds, 2 and 9 were moderate inhibitors and decreased the rate of pNPA hydrolysis by about 50%. By comparison, compounds 12 and 13 were much more effective CA inhibitors and decreased the rate of hydrolysis to approximately that observed in the presence of AAA, which is recognized as a strong CA inhibitor (Fig. 5c-f) .
Inhibition studies with potential decomposition products
In addition to the 15 compounds examined above, we also investigated the CA inhibition properties of thiophenol and benzyl thiol because these thiols could potentially be generated as hydrolysis and/or decomposition products of 2, 9, 12, and 13. (vide infra). We found both thiophenol and benzyl thiol to inhibit CA (Fig. 5g) . The rate of hydrolysis in the presence of thiophenol alone was found to be similar to that of 12 and 13, both of which, if deprotonated, would decompose to thiophenol. Similarly, the rate of pNPA hydrolysis observed in the presence of benzyl thiol is similar to that of 2 and 9, which would decompose to benzyl thiol.
Discussion
The recent introduction and adoption of triggered COSreleasing compounds for H 2 S donation highlights the potential of this strategy to access a broad class of H 2 S donors with potential therapeutic properties. In addition to providing functional COS/ H 2 S donor platforms, the use of analogous CO 2 /H 2 O-releasing compounds provides key control compounds that undergo the same self-immolative chemistry to generate the same organic byproducts as the canonical donors, but which do not release COS/H 2 S. For all such scaffolds, a key component of the COS/H 2 S donor strategy is the requirement of CA-mediated COS hydrolysis to H 2 S. Because of this requirement, the donor motifs should not interfere with CA activity. With these considerations in mind, we wanted to measure cytotoxicity profiles and CA inhibition data for these potential COS-releasing moieties to help determine the most promising scaffolds for caged COS release.
We identified a library of 15 compounds that include known and potential caged COS scaffolds, caged CO 2 and CS 2 motifs, and related control compounds as described in the Results section. Although each of these compounds represents a scaffold that could be used in a donor or control compound, they do not contain triggering moieties to allow for decomposition, meaning that they should not release COS spontaneously. By investigating the cytotoxicity and CA inhibition profile of each core motif, we hoped to identify the core structures that do not affect CA activity for future COS/H 2 S donor design.
As outlined in the Results section, none of the prepared model compounds were found to be cytotoxic in A549 cells at concentrations below 100 mM, suggesting that the core motifs are not inherently cytotoxic at concentration ranges typically used in H 2 S donation studies. Of the 15 compounds investigated, however, we did identify four compounds that inhibit CA activity: 2, 9, 12, and 13 (Fig. 6a) . At first, the only similarity between these compounds appeared to be the presence of a sulfur atom adjacent to the thiocarbonyl moiety. We also noticed, however, that deprotonation of the amide NH in these compounds could lead to decomposition to form a thiol-containing byproduct (benzyl thiol for 2 and 9 or thiophenol for 12 and 13, Fig. 6b ). We hypothesized that these thiol byproducts may be responsible for the observed inhibitory properties, rather than the thiocarbamate/dithiocarbamate scaffolds directly. Further supporting this hypothesis, we measured the inhibitory effects of benzyl thiol and thiophenol. Benzyl thiol exhibited similar CA inhibitory profiles to 2 and 9, and thiophenol inhibited CA similarly to 12 and 13. Aside from the shown CA inhibition properties, this additionally suggests the instability of these scaffolds at even moderately basic conditions, making them less reliable as COS donor constructs or as suitable controls.
In combination with recent work investigating stability and rate of COS/H 2 S release from different COS-releasing scaffolds [22] , the present work provides an important resource for selecting the best scaffolds for COS donation in the design of H 2 S therapeutics. Four scaffolds (1, 3, 4, and 5) were identified that have either been reported to release COS or are likely to release COS through selfimmolation that do not inhibit CA. These motifs are likely ideal starting points in the design of new COS/H 2 S donor motifs. Although this work provides the first insights into the potential CA inhibition properties of COS/H 2 S donor scaffolds, any structural modifications could impact the extent of inhibition, which will likely require future constructs to be tested for CA inhibition directly. Additionally, the identification of thiocarbamate 2 as a CA inhibitor should not completely eliminate this S-alkyl thiocarbamate motif from consideration as a COS/H 2 S donor core, because further functionalization of the core structure may impact or reduce the CA inhibition profiles. Indeed, similar scaffolds have been shown to be successful COS donors in recent reports [15, 17] . Future work is required to determine the precise consequences of using a COS donor that inhibits CA as an H 2 S donor, but the efficiency, rate of decomposition, and rate of H 2 S production may all be affected. Through the rational selection of COS donor cores that provide efficacious COS/H 2 S release rates, suitable stability in the presence of biological milieu, and minimal CA inhibition, we expect the field of COS/H 2 S donors will continue to expand rapidly and provide access to new motifs with pharmacologically-relevant activities.
